Although PARPi are active in HR‐deficient cancers, particularly those lacking BRCA1/2, their utility is limited by the development of resistance which may occur through restoration of HR function.[135] These BRCA‐deficient cells rely heavily on cell‐cycle regulators to reverse the effects of PARP inhibition and become PARPi‐resistant cells. Here, BRCA1 is linked to cancer.